Stock Events

Stock Events

Aptose Biosciences 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LTIA.STU. It's not an investment recommendation.
BCE
6
BCE.TO
Canadian Imperial Bank Of Commerce
6
CM.TO
Microsoft
5
MSFT
Enbridge
5
ENB.TO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap2.22B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, directly competing in the oncology and hematology space similar to Aptose's focus.
Incyte
INCY
Mkt Cap23.35B
Incyte Corporation specializes in oncology products, directly competing with Aptose in developing treatments for hematologic cancers.
TG Therapeutics
TGTX
Mkt Cap8.16B
TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, overlapping with Aptose's research in hematologic malignancies.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences is a large biopharmaceutical company with a strong presence in oncology and hematology, making it a direct competitor.
Novartis
NVS
Mkt Cap305.1B
Novartis AG, with its extensive portfolio in healthcare, including treatments for cancer, competes in the same market as Aptose, especially in oncology.
AMGEN
AMGN
Mkt Cap201.93B
Amgen focuses on human therapeutics, including oncology/hematology, which puts it in direct competition with Aptose's cancer research efforts.
Karyopharm Therapeutics
KPTI
Mkt Cap218.02M
Karyopharm Therapeutics is involved in the discovery and development of drugs for the treatment of cancer, including hematologic malignancies, similar to Aptose's focus.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a strong portfolio in oncology, including treatments for hematologic cancers, making it a competitor in the same therapeutic area as Aptose.

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Show more...
CEO
Dr. William G. Rice Ph.D.
Employees
14
Country
Canada
ISIN
CA03835T2002

Listings

F
DE
LTI0.F
STU
DE
LTI0.STU
STU
DE
LTIA.STU
US
APTOF

0 Comments

Share your thoughts

FAQ

What is Aptose Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Aptose Biosciences stocks are traded under the ticker LTIA.STU.
How many employees does Aptose Biosciences have?▼
As of July 10, 2026, the company has 14 employees.
In which sector is Aptose Biosciences located?▼
Aptose Biosciences operates in the Other sector.
When did Aptose Biosciences complete a stock split?▼
Aptose Biosciences has not had any recent stock splits.
Where is Aptose Biosciences headquartered?▼
Aptose Biosciences is headquartered in Toronto, Canada.